PCI Biotech Holding ASA (PCIB.OL)
- Previous Close
1.7480 - Open
1.7000 - Bid 1.6460 x 20000
- Ask 1.6900 x 12500
- Day's Range
1.6000 - 1.7000 - 52 Week Range
1.2000 - 3.4000 - Volume
82,426 - Avg. Volume
87,228 - Market Cap (intraday)
63.306M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7900 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
www.pcibiotech.comRecent News: PCIB.OL
Performance Overview: PCIB.OL
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PCIB.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PCIB.OL
Valuation Measures
Market Cap
65.25M
Enterprise Value
20.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.69
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.85%
Return on Equity (ttm)
-42.13%
Revenue (ttm)
2.99M
Net Income Avi to Common (ttm)
-20.32M
Diluted EPS (ttm)
-0.7900
Balance Sheet and Cash Flow
Total Cash (mrq)
41.18M
Total Debt/Equity (mrq)
0.82%
Levered Free Cash Flow (ttm)
-8.74M
Company Insights: PCIB.OL
PCIB.OL does not have Company Insights